TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS-790052) for HCV genotype-1 patients

We are very excited to work with Bristol-Myers Squibb to investigate TMC435 in combination with an NS5A replication complex inhibitor.
Read more

 

Very sizeable and growing need for improved HCV medicines

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately three percent of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost three million people in the United States are chronically infected with HCV.

Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 3 clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.